Fig. 7

Predictive power of longitudinal reactivity of HBV-specific T cells for liver hepatitis progression in CHB patients. 33 CHB patients undergoing NUCs or NUCs/INF-α treatment were divided into normal (ALT < 40 IU/L) group and abnormal (ALT > 40 IU/L) group of liver function at 6 months (normal/abnormal: 8/25) or 12 months (normal/abnormal: 6/27) after the last test of HBV-specific T cells. ROC curve analyses of single test and combined tests of HBV-specific T cells (SFUs/2 × 10⁵ PBMCs) were performed to predict hepatitis progression at 6 months (A) and 12 months after the last test (B) of HBV-specific T cells, using R package pROC, and summarized in table. The p¹ values represent the significance of model. The p² values represent the significance of difference between the AUC of combined markers (First + Second + Third) and other predictors